DAFTAR RUJUKAN

1. Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA. Comparison of quetiapine and risperidone in the treatment of schizophrenia : a randomized, double-blind, flexible-dose, 8- week study. J Clin Psychiatry. 2006 ; 67 : 1093-03. 2. Miodownik C, Lerner V. Quetiapine : efficacy, tolerability and safety in schizophrenia. Expert Rev. Neurotherapeutics. 2006 ; (7) : 983-92. 3. Cheer SM, Wagstaff AJ. Quetiapine : a review of its use in the management of schizophrenia. CNS Drugs. 2004 ; 18 (3) : 173-99. 4. Timdahl K, Carlsson A, Stening G. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms. Available from : http : // www.interscience.wiley.com. 5. Citrome L, Jaffe A, Levine J, Lindenmayer JP. Dosing of quetiapine in schizophrenia : how clinical practice differs from registration studies. J Clin Psychiatry. 2005 ; 66 : 1512-16. 6. Schatzberg AF, Nemeroff CB. Textbook of psychopharmacology. 4thed. London : American Psychiatric Publishing : 2009. 7. Sadock BJ, Sadock VA. Kaplan & sadocks synopsis of psychiatry behavioral sciences / clinical Psychiatry.10thed. Philadelphia : Lippincott Williams & Wilkins ; 2007. 8. Small JG, Kolar MC, Kellams JJ. Quetiapine in schizophrenia : onset of action within the first week of treatment. Current Medical Research and Opinion. 2004 ; 20 (7) : 1017-20. 9. Sparshatt A, Jones S, Taylor D. Quetiapine : dose-response relationship in schizophrenia. CNS Drugs. 2008 ; 22 (1) : 49-68. 10. Stern RG, Kahn RS, Harvey PD, Amin F, Apter SH, Hirschowitz J. Early response to haloperidol treatment in chronic schizophrenia. Schizophrenia Research. 1993 ; 10 ; 165-71. 11. Palao DJ, Arauxo A, Brunet M, Marquez M, Bernardo M, Ferrer J, et al. Positive versus negative symptoms in schizophrenia : response to haloperidol. Neuro-Psychopharmacol & Biol. Psychiat. 1994 ; 18 : 155-64. 12. van Kammen DP, Marder SR. Serotonin-dopamine antagonists (atypical or second-generation antipsychotics ). In :Kaplan & sadocks, editors. Comprehensive textbook of psychiatry. 8thed. Philadelphia : Lippincott Williams & Wilkins ; 2005. p. 2929-31. 13. Astra Zeneca Neuroscience. Seroquel : efficacy and tolerability in schizophrenia : Astra Zeneca ; 2003. 14. Schulz SC, Thomson R, Brecher M. The efficacy of quetiapine vs haloperidol and placebo : a meta-analytic study of efficacy. Schizophrenia Research. 2003 ; 62 : 1-12. 15. Peuskens J, Kasper S, Arango C, Bandinelli PL, Gastpar M, Keks N, et al. Management of acutely ill patients in the hospital setting : focus on quetiapine. International Journal of Psychiatry in Clinical Practice. 2007 ; 11 (1) : 61-72.

Universitas Sumatera Utara

16. Arango C, Bobes J. Managing acute exacerbations of schizophrenia : focus on quetiapine. Current Medical Research and Opinion. 2004 ; 20 (5) : 61926. 17. Stahl SM. Essential psychopharmacology, neuroscientific basis and practical applications. 2nded. New York : Cambridge University Press ; 2000. 18. Meltzer HY, Fatemi SH. Schizophrenia. In : Ebert MH, Loosen PT, Nurcombe B, ed. Current diagnosis & treatment in psychiatry. Singapore : McGraw-Hill ; 2000.p. 263-4. 19. Stahl SM. Essential psychopharmacology of antipsychotics and mood stabilizers. Cambridge : Cambridge University Press ; 2002. 20. Kane JM, Marder SR. Schizophrenia : Somatic treatment. In :Kaplan & sadocks, editors. Comprehensive textbook of psychiatry. 8thed. Philadelphia : Lippincott Williams & Wilkins ; 2005. p. 1468-9. 21. Marder SR, van Kammen DP. Dopamine receptor antagonists (typical antipsychotics). In :Kaplan & sadocks, editors. Comprehensive textbook of psychiatry. 8thed. Philadelphia : Lippincott Williams & Wilkins ; 2005. p. 2817,2822. 22. Stahl SM. Essential psychopharmacology, the prescribers guide. 1sted. New York : Cambridge University Press ; 2005. 23. Arana GW, Rosenbaum JF. Handbook of psychiatric drug therapy. 4thed. Philadelphia : Lippincott Williams & Wilkins ; 2000. 24. Janssen Pharmaceutica NV. Haldol brand of haloperidol injection. 2005 : 1-12. 25. Arango C, Bernardo M. The effect of quetiapine on aggression and hostility in patients with schizophrenia. Hum Psychopharmacol Clin Exp. 2005 ; 20 : 237 241. 26. Sadock BJ, Sadock VA. Kaplan & sadocks pocket handbook of psychiatric drug treatment. 3rded. Philadelphia : Lippincott Williams & Wilkins ; 2001. 27. Albers LJ, Hahn RK, Reist C. Handbook of psychiatric drugs. 2008ed. USA : Current Clinical Strategies Publishing ; 2008. 28. Schatzberg AF, Cole JO, De Battista C. Manual of clinical psychopharmacology. 4thed. Washington : American Psychiatric Publishing ; 2003. 29. Fatemi SH. Schizophrenia. In : Fatemi SH, Clayton PJ, editors. The medical basis of psychiatry. 3rded. USA : Human Press ; 2008. p. 98. 30. Herz MI, Marder SR. Schizophrenia : comprehensive treatment and management. Philadelphia: Lippincott Williams & Wilkins;2002. 31. Astra Zeneca Neuroscience. Modul 3 : quetiapine in the management of schizophrenia. Jakarta : Astra Zeneca . 32. The Canadian Journal of Psychiatry La Revue Canadienne De Psychiatrie. Clinical practice guideline treatment of schizophrenia. Can J Psychiatry. 2005 ; 50 ; (suppl 1) : 22S. 33. Nasrallah HA, Tandon R. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia. J Clin Psychiatry. 2002 : 63 (suppl 13) : 1220.

Universitas Sumatera Utara

34. Arvanitis LA, Miller BG, the Seroquel Trial 13 Study Group. Multiple fixed doses of seroquel (quetiapine) in patients with acute exacerbation of schizophrenia : a comparison with haloperidol an placebo. Biol Psychiatry. 1997 ; 42 : 233-46. 35. Astra Zeneca Neuroscience. Serequel (quetiapine) : Astra Zeneca ; 2003. 36. Kay SR. Positive and negative syndromes in schizophrenia. New York : Bruner/ Mazel ; 1991. 37. Harun SR, Putra ST, Wiharta AS, Chair I. Uji klinis. Dalam : Sastroasmoro S, Ismael S, penyunting. Dasar dasar metodologi penelitian klinis. Edisi ke-2. Jakarta : Sagung Seto ; 2006. h.144-63 38. Sastroasmoro S. Pemilihan subyek penelitian. Dalam : Sastroasmoro S, Ismael S, penyunting. Dasar dasar metodologi penelitian klinis. Edisi ke2. Jakarta : Sagung Seto ; 2006. h. 67-76. 39. Madiyono B, Moeslichan S, Sastroasmoro S, Budiman I, Purwanto SH. Perkiraan besar sampel. Dalam : Sastroasmoro S, Ismael S, penyunting. Dasar dasar metodologi penelitian klinis. Edisi ke-2. Jakarta : Sagung Seto ; 2006. h. 259-86. 40. Dahlan MS. Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan. Edisi ke-2. Jakarta : Salemba Medika ; 2009. 41. Departemen Kesehatan Republik Indonesia. Pedoman penggolongan dan diagnosis gangguan jiwa di Indonesia III . Jakarta ; 1993. 42. Tumbelaka AR, Riono P, Sastroasmoro S, Wirjodiarjo M, Pudjiastuti P, Firman K. Pemilihan uji hipotesis. Dalam : Sastroasmoro S, Ismael S, penyunting. Dasar-dasar metodologi penelitian klinis. Edisi ke-2. Jakarta : Sagung Seto ; 2006. h. 240-257. 43. Wahyuni AS. Statistika kedokteran. Edisi ke-1. Jakarta : Bamboedoea Communication ; 44. Pedoman definisi PANSS. Bagian Psikiatri Fakultas Kedokteran Universitas Indonesia. Jakarta, 1994. 45. Lubis CP, Lubis M, Pasaribu S, Daulay RM, Ali M. Pedoman penulisan usulan penelitian dan tesis. Edisi ke-1. Medan : USU Press ; 2009.

Universitas Sumatera Utara